The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

For comparison, Imfinzi given on its own every four weeks achieved an OS of 13.6 months, while for a regimen of tremelimumab alone it was 15.1 months and 11.3 months for another regimen based on ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.